A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

NCT04734262 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Sitravatinib
DRUG: Tislelizumab
DRUG: Nab-paclitaxel

Sponsor

Fudan University